Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC

Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2017-10, Vol.28 Suppl 9, p.ix73
Hauptverfasser: Satouchi, Miyako, Hotta, Katsuyuki, Nosaki, Kaname, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Aoe, Keisuke, Noguchi, Kazuo, Shimamoto, Takashi, Rangwala, Reshma, Brahmer, Julie
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page ix73
container_title Annals of oncology
container_volume 28 Suppl 9
creator Satouchi, Miyako
Hotta, Katsuyuki
Nosaki, Kaname
Takahashi, Toshiaki
Nakagawa, Kazuhiko
Aoe, Keisuke
Noguchi, Kazuo
Shimamoto, Takashi
Rangwala, Reshma
Brahmer, Julie
description
doi_str_mv 10.1093/annonc/mdx619
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32120654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2809-b369cf9f54e3c631c5267089b8fff2ffd8344d90624be5a6890dd02fffc271873</originalsourceid><addsrcrecordid>eNo9kDFOwzAYhS0EoqUwsiIvbJj-thMnRgIJhQKBqI3UMjBFTmKLQpNUcYIoEyun4RDchJNQFGB4esP79IYPoX0KxxQkH6qyrMpsWOQvgsoN1KeukMQHh26iPkjGiedyp4d2rH0EACGZ3EY9zigD4Tp99HSjlqrEtk2tbnBlcPygrMZhGGLbtPkK347ux5PZiABzTnCsi7SuFvPXtlApNlWN4wsSUTyLp19v72frnLpweISbWqum0GVDSvX58azxeBpEwS7aMmph9d5vD9Dd5WgWXJNochUG5xHJmA-SpFzIzEjjOppngtPMZcIDX6a-MYYZk_vccXIJgjmpdpXwJeQ5rAeTMY_6Hh8g0v1mdWVtrU2yrOeFqlcJheRHWtJJSzppa_6g45dtWuj8n_6zxL8BYQVpbg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS &gt; =50%, treatment-naïve NSCLC</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Satouchi, Miyako ; Hotta, Katsuyuki ; Nosaki, Kaname ; Takahashi, Toshiaki ; Nakagawa, Kazuhiko ; Aoe, Keisuke ; Noguchi, Kazuo ; Shimamoto, Takashi ; Rangwala, Reshma ; Brahmer, Julie</creator><creatorcontrib>Satouchi, Miyako ; Hotta, Katsuyuki ; Nosaki, Kaname ; Takahashi, Toshiaki ; Nakagawa, Kazuhiko ; Aoe, Keisuke ; Noguchi, Kazuo ; Shimamoto, Takashi ; Rangwala, Reshma ; Brahmer, Julie</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx619</identifier><identifier>PMID: 32120654</identifier><language>eng</language><publisher>England</publisher><ispartof>Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix73</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2809-b369cf9f54e3c631c5267089b8fff2ffd8344d90624be5a6890dd02fffc271873</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27928,27929</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32120654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Satouchi, Miyako</creatorcontrib><creatorcontrib>Hotta, Katsuyuki</creatorcontrib><creatorcontrib>Nosaki, Kaname</creatorcontrib><creatorcontrib>Takahashi, Toshiaki</creatorcontrib><creatorcontrib>Nakagawa, Kazuhiko</creatorcontrib><creatorcontrib>Aoe, Keisuke</creatorcontrib><creatorcontrib>Noguchi, Kazuo</creatorcontrib><creatorcontrib>Shimamoto, Takashi</creatorcontrib><creatorcontrib>Rangwala, Reshma</creatorcontrib><creatorcontrib>Brahmer, Julie</creatorcontrib><title>Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS &gt; =50%, treatment-naïve NSCLC</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNo9kDFOwzAYhS0EoqUwsiIvbJj-thMnRgIJhQKBqI3UMjBFTmKLQpNUcYIoEyun4RDchJNQFGB4esP79IYPoX0KxxQkH6qyrMpsWOQvgsoN1KeukMQHh26iPkjGiedyp4d2rH0EACGZ3EY9zigD4Tp99HSjlqrEtk2tbnBlcPygrMZhGGLbtPkK347ux5PZiABzTnCsi7SuFvPXtlApNlWN4wsSUTyLp19v72frnLpweISbWqum0GVDSvX58azxeBpEwS7aMmph9d5vD9Dd5WgWXJNochUG5xHJmA-SpFzIzEjjOppngtPMZcIDX6a-MYYZk_vccXIJgjmpdpXwJeQ5rAeTMY_6Hh8g0v1mdWVtrU2yrOeFqlcJheRHWtJJSzppa_6g45dtWuj8n_6zxL8BYQVpbg</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Satouchi, Miyako</creator><creator>Hotta, Katsuyuki</creator><creator>Nosaki, Kaname</creator><creator>Takahashi, Toshiaki</creator><creator>Nakagawa, Kazuhiko</creator><creator>Aoe, Keisuke</creator><creator>Noguchi, Kazuo</creator><creator>Shimamoto, Takashi</creator><creator>Rangwala, Reshma</creator><creator>Brahmer, Julie</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201710</creationdate><title>Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS &gt; =50%, treatment-naïve NSCLC</title><author>Satouchi, Miyako ; Hotta, Katsuyuki ; Nosaki, Kaname ; Takahashi, Toshiaki ; Nakagawa, Kazuhiko ; Aoe, Keisuke ; Noguchi, Kazuo ; Shimamoto, Takashi ; Rangwala, Reshma ; Brahmer, Julie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2809-b369cf9f54e3c631c5267089b8fff2ffd8344d90624be5a6890dd02fffc271873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Satouchi, Miyako</creatorcontrib><creatorcontrib>Hotta, Katsuyuki</creatorcontrib><creatorcontrib>Nosaki, Kaname</creatorcontrib><creatorcontrib>Takahashi, Toshiaki</creatorcontrib><creatorcontrib>Nakagawa, Kazuhiko</creatorcontrib><creatorcontrib>Aoe, Keisuke</creatorcontrib><creatorcontrib>Noguchi, Kazuo</creatorcontrib><creatorcontrib>Shimamoto, Takashi</creatorcontrib><creatorcontrib>Rangwala, Reshma</creatorcontrib><creatorcontrib>Brahmer, Julie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Satouchi, Miyako</au><au>Hotta, Katsuyuki</au><au>Nosaki, Kaname</au><au>Takahashi, Toshiaki</au><au>Nakagawa, Kazuhiko</au><au>Aoe, Keisuke</au><au>Noguchi, Kazuo</au><au>Shimamoto, Takashi</au><au>Rangwala, Reshma</au><au>Brahmer, Julie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS &gt; =50%, treatment-naïve NSCLC</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2017-10</date><risdate>2017</risdate><volume>28 Suppl 9</volume><spage>ix73</spage><pages>ix73-</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pmid>32120654</pmid><doi>10.1093/annonc/mdx619</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix73
issn 0923-7534
1569-8041
language eng
recordid cdi_crossref_primary_10_1093_annonc_mdx619
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T23%3A29%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Japan%20subset%20of%20Phase%20III%20study%20KEYNOTE-024:%20Pembrolizumab%20for%20PD-L1%20TPS%E2%80%89%3E%E2%80%89=50%25,%20treatment-na%C3%AFve%20NSCLC&rft.jtitle=Annals%20of%20oncology&rft.au=Satouchi,%20Miyako&rft.date=2017-10&rft.volume=28%20Suppl%209&rft.spage=ix73&rft.pages=ix73-&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx619&rft_dat=%3Cpubmed_cross%3E32120654%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32120654&rfr_iscdi=true